Business

Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial

Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.

adminadmin
Jun 21, 2024 - 02:00
 0  16
Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
Read More

Tags:

Previous Article

Fast-food customers are shifting to casual-dining chains, Darden Restaurants CEO...

Next Article

Darden beats on earnings, even as Olive Garden, fine-dining sales drag

admin
admin

Related Posts

Colliers CEO: Commercial real estate still has some stress to come and loans to be worked out

Colliers CEO: Commercial real estate still has some str...

admin Sep 20, 2024  0  9

Google-backed Tempus AI closes first day of trading up 9% in Nasdaq stock market debut

Google-backed Tempus AI closes first day of trading up ...

admin Jun 15, 2024  0  5

This ETF is trying to satisfy appetites for weight loss stocks

This ETF is trying to satisfy appetites for weight loss...

admin Jul 7, 2024  0  4